Abstract
We investigated the role of protein kinase C (PKC) in insulin-induced c-Jun N-terminal kinase (JNK) activation in rat 1 fibroblasts expressing human insulin receptors. Insulin treatment led to increased SAPK/ERK kinase 1 (SEK1) phosphorylation, and then stimulated JNK activity in a dose- and time-dependent manner, as measured either by a solid-phase kinase assay using glutathione S-transferase (GST)-c-Jun fusion protein as a substrate, or by quantitation of the levels of phosphorylated JNK by Western blotting using anti-phospho-JNK antibody. Insulin-induced JNK activation was potentiated by either preincubating cells with 2 nM GF109203X (PKC inhibitor) or down-regulation of PKC by overnight treatment with 100 nM tetradecanoyl phorbol acetate. In contrast, brief preincubation with 100 nM tetradecanoyl phorbol acetate inhibited the insulin- induced JNK activation. Furthermore, we found that 5 microM rottlerin, a PKCdelta inhibitor, enhanced insulin-induced JNK activation, but a PKCbeta inhibitor, LY333531, had no effect. Consistent with these findings, overexpression of PKCdelta led to decreased insulin-induced JNK activation, whereas overexpression of PKCbeta had no effect. Although overexpression of wild-type PKCdelta attenuated insulin-induced JNK activation, a kinase-dead PKCdelta mutant did not cause such attenuation. Finally, we found that the magnitude of insulin-induced JNK activation was inversely correlated with the expression level of PKCdelta among different cell lines. In conclusion, the expression of PKCdelta may negatively regulate insulin-induced JNK activation.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetophenones / pharmacology
-
Animals
-
Benzopyrans / pharmacology
-
Cell Cycle Proteins*
-
Cell Line
-
Dual Specificity Phosphatase 1
-
Enzyme Activation / drug effects
-
Enzyme Inhibitors / pharmacology
-
Fibroblasts / enzymology
-
Gene Expression
-
Glutathione Transferase / genetics
-
Glutathione Transferase / metabolism
-
Humans
-
Immediate-Early Proteins / metabolism
-
Insulin / pharmacology*
-
Isoenzymes / antagonists & inhibitors
-
Isoenzymes / genetics
-
Isoenzymes / pharmacology*
-
JNK Mitogen-Activated Protein Kinases*
-
MAP Kinase Kinase 4*
-
Mitogen-Activated Protein Kinase Kinases / genetics
-
Mitogen-Activated Protein Kinase Kinases / metabolism*
-
Phosphoprotein Phosphatases*
-
Phosphorylation
-
Protein Kinase C / antagonists & inhibitors
-
Protein Kinase C / genetics
-
Protein Kinase C / pharmacology*
-
Protein Phosphatase 1
-
Protein Tyrosine Phosphatases / metabolism
-
Proto-Oncogene Proteins c-jun / genetics
-
Proto-Oncogene Proteins c-jun / metabolism
-
Rats
-
Receptor, Insulin / genetics
-
Recombinant Fusion Proteins / metabolism
-
Tetradecanoylphorbol Acetate / pharmacology
Substances
-
Acetophenones
-
Benzopyrans
-
Cell Cycle Proteins
-
Enzyme Inhibitors
-
Immediate-Early Proteins
-
Insulin
-
Isoenzymes
-
Proto-Oncogene Proteins c-jun
-
Recombinant Fusion Proteins
-
rottlerin
-
Glutathione Transferase
-
Receptor, Insulin
-
Protein Kinase C
-
JNK Mitogen-Activated Protein Kinases
-
MAP Kinase Kinase 4
-
MAP2K4 protein, human
-
Mitogen-Activated Protein Kinase Kinases
-
Phosphoprotein Phosphatases
-
Protein Phosphatase 1
-
DUSP1 protein, human
-
Dual Specificity Phosphatase 1
-
Dusp1 protein, rat
-
Protein Tyrosine Phosphatases
-
Tetradecanoylphorbol Acetate